

Manuscript no. HAEMATOL/2012/062539 entitled "Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia"

Authors: Judith E. Karp, Elizabeth L. Garrett-Mayer, Elihu H. Estey, Michelle A. Rudek, B. Douglas Smith, Jacqueline M. Greer, D. Michelle Drye, Karen Mackey, Kathleen Shannon Dorcy, Steven D. Gore, Mark J. Levis, Michael A. McDevitt, Hetty E. Carraway, Keith W. Pratz, Douglas E. Gladstone, Margaret M. Showel, Megan Othus, L. Austin Doyle, John J. Wright, and John M. Pagel.

Information about the contributions of each person named as having participated in the study

1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:
• Judith E Karp, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center,
jkarp2@jhmi.edu

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_1author.html): "Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship".

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the **conception of the study**: Judith E. Karp, Elizabeth Garrett-Mayer

3) **Design & Methods**. The following authors were responsible for specific investigations (please detail):

- Judith E. Karp, Elizabeth Garrett-Mayer, Elihu H. Estey, B. Douglas Smith, L. Austin Doyle, John J. Wright, and John M. Pagel were responsible for clinical trial design and statistical considerations
- Michelle Rudek was responsible for design of pharmacokinetic studies
- Jacqueline M. Greer was responsible for multicenter coordination

4) **Results**. The following authors were responsible for specific portions of the results, including figures and tables (please indicate the person responsible for each figure and each table):

- Judith E Karp, Elizabeth Garrett-Mayer, Elihu H. Estey, B. Douglas Smith, and John Pagel were responsible for demographics, comparative toxicities, and comparative clinical outcomes
- Judith E Karp designed tables 1-3
- Michelle Rudek designed Figure 1 and was responsible for pharmacokinetics
- Elizabeth Garrett-Mayer designed figures 2 A and B and 3 A-D
- Elizabeth Garrett-Mayer and Megan Othus performed statistical analyses
- Jacqueline M. Greer, D. Michelle Drye, Karen Mackey, and Kathleen Shannon Dorcy collected data and assisted with data analysis
- Steven D, Gore, Mark J. Levis, Michael A. McDevitt, Hetty E. Carraway, Keith W. Pratz, Douglas E. Gladstone, and Margaret M. Showel provided toxicity and clinical outcomes data and assisted with data analysis
- L. Austin Doyle and John J. Wright provided critical data analysis

5) Writing the manuscript. The following authors were responsible for writing the manuscript:

- Judith E. Karp, Elizabeth Garrett-Mayer, Elihu H. Estey and John Pagel were responsible for writing the manuscript
- B. Douglas Smith, Steven D. Gore, Mark J. Levis, Michael A. McDevitt, Hetty E. Carraway, Keith W. Pratz, Douglas E. Gladstone, Margaret M. Showel, Megan Othus, L. Austin Doyle and John J. Wright edited the manuscript

6) Contributors Listed in Acknowledgments:

The authors thank the Johns Hopkins Sidney Kimmel Cancer Center and Fred Hutchinson Cancer Research Center nursing staffs for superb medical care, and the patients and their families, without whose partnership we could never have conducted the trial and from whom we have learned critical information that will help us to improve the treatment of these diseases. We also thank Christy Stewart for her expert administrative support. This work was supported in part by NCI Cooperative Agreement U01 CA70095 (J.E.K. and M.A.R.), NCI Cancer Center Support Grant 2P30 CA06973-46, National Center for Research Resources Grant UL1 RR025005 (a component of the National Institutes of Health Roadmap for Medical Research), and philanthropic funds from Dr. Robert E. Fischell in memory of his late wife Marian (J.E.K.). The contents of the project are solely the responsibility of the authors and do not necessarily represent the official view of NCI, NCR, or NIH.